Tel Aviv, Israel and Vienna, Austria (ots/PRNewswire) - Isotopia
Molecular Imaging and Seibersdorf Labor are pleased to announce that
they have entered into an agreement for the production of
no-carrier-added Lutetium-177, a critical medical radioisotope used
in the manufacturing of radiopharmaceuticals for treatment of many
types of cancer, including neuroendocrine tumors and prostate cancer.
Seibersdorf Labor, a GMP Contract manufacturing of
radiopharmaceuticals, a global leader in the development, production
and commercialization of radiopharmaceuticals, will produce 177Lu
n.c.a in collaboration with Isotopia Molecular Imaging for
distribution in Europe.
Isotopia has selected Seibersdorf, located in Austria, following a
year-long evaluation process that included the review several
proposals from sites across Europe. It was selected due to the high
level of expertise on site, the GMP infrastructure and the team's
enthusiasm to manufacture lifesaving radiopharmaceuticals. In
addition, the location provides easy and safe land transportation
access to the European market.
The production facility is expected to be ready by Q4 2022.
177Lu n.c.a is used in Targeted Radionuclide Therapy in the field of
Precision Oncology. By binding n.c.a. Lu-177 isotopes to
tumor-specific targeting molecules, the resulting radiopharmaceutical
targets the tumor and delivers precise cell-killing radiation that
spares normal healthy tissue. Isotopia has developed a reliable and
unique GMP method to produce a highly pure form of Lu-177. 177Lu
n.c.a contains no Mercury (Hg) and no metastable Lu-177m, therefore
there is no need for cost intensive clinical waste management.
Isotopia's CEO & Co-Founder Dr. Eli Shalom stated: This step supports
Isotopia's global strategy to simplify and shorten the supply route
to our customers. We are working intensively to complete our plan to
establish a production site in each continent. This, to provide a
total solution to pharma companies and hospitals together with
labeling services. The production and labeling facility in
Seibersdorf Laboratories will be the best solution for Europe,
enabling Isotopia to deliver a reliable, flexible, and most
important, secure land supply of a broad range of critical medical
isotopes to European customers, starting with Lu177 n.c.a. We have
found in Seibersdorf the best partner sharing the same vision to save
Seibersdorf's CEO, Martina Schwaiger stated: "The new production
agreement is an exciting opportunity for our organization and we are
pleased to be working with Isotopia Molecular Imaging on this
important sector of medical care."
Isotopia and Seibersdorf intend to expand their partnership to
include commercial-scale production of 177Lu n.c.a and labeling
services to meet future commercial market demand. In addition, both
companies have also committed to collaborate on the development of
GMP manufacturing processes for other emerging medical isotopes.
About Seibersdorf Labor GmbH
Seibersdorf Labor GmbH is an Austrian company specialized in high
quality laboratory and analysis work, application-oriented research
and development as well as consulting and training.
The teams of Seibersdorf Laboratories are service, know-how and
technology provider and cover a broad area of scientific expertise:
development, production and quality control of radiopharmaceuticals,
anti-doping and forensic analysis, radiation protection, ionizing and
non-ionizing radiation, radio frequency engineering and
The experts of Seibersdorf Laboratories represent Austria on various
For more information visit: www.seibersdorf-laboratories.at
Contact: Roland Müller, Head Pharmaceuticals, +43 50 550 3470,
Isotopia Molecular Imaging Ltd. is a collaboration between The
Metrontario Group and Israel's leading scientists in the field of
The experienced Isotopia team, together with its nuclear pharmacy,
cyclotron facility, Lu-177 production site, and sterile manufacturing
plant, are a well-established platform for development. By creating
collaborations between the scientific and medical community, Isotopia
further develops and experiment with new markers for imaging
applications and molecular therapy. For more information about
Isotopia, please visit: www.isotopia.co.il
Molecular Imaging Ltd.Business Development
Digital press kit: http://www.ots.at/pressemappe/PR159381/aom
Der Podcast für junge Anleger jeden Alters
Wiener Börse Plausch #24: Über S Immo, Valneva, Porr und ein Tier mit der Arschkarte
Aktien auf dem Radar:Porr, UBM, DO&CO, Telekom Austria, Kapsch TrafficCom, Lenzing, Zumtobel, SBO, VIG, voestalpine, Wolford, Frequentis, CA Immo, AMS, Cleen Energy, Frauenthal, Heid AG, Marinomed Biotech, Österreichische Post, startup300, Amag, Merck Co., BMW, Deutsche Post, Continental, Fresenius, Covestro, Deutsche Telekom, Bayer, HeidelbergCement, Noratis.
PwC ist ein Netzwerk von Mitgliedsunternehmen in 157 Ländern. Mehr als 276.000 Mitarbeiterinnen und Mitarbeiter erbringen weltweit qualitativ hochwertige Dienstleistungen in den Bereichen Wirtschaftsprüfung, Steuer- und Rechtsberatung sowie Unternehmensberatung.
>> Besuchen Sie 67 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER